UK markets open in 4 hours 31 minutes

Novozymes A/S (NVZMY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
52.36-0.58 (-1.09%)
At close: 03:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous close52.94
BidN/A x N/A
AskN/A x N/A
Day's range52.25 - 53.07
52-week range45.97 - 71.14
Avg. volume27,685
Market cap14.483B
Beta (5Y monthly)0.41
PE ratio (TTM)27.13
EPS (TTM)1.93
Earnings dateN/A
Forward dividend & yield0.88 (1.66%)
Ex-dividend date06 Mar 2023
1y target est51.23
  • Globe Newswire

    Novozymes delivers historically strong full-year results

    Novozymes is delivering strong growth and earnings in a volatile market environment with 9% organic sales growth in 2022. This marks the highest organic sales growth in more than a decade, and Novozymes is confident about the 2023 outlook of 4-7%. COPENHAGEN, Denmark – January 26, 2026. In the 2022 financial year, Novozymes delivers 9% organic sales growth – 11% organic sales growth in the fourth quarter alone – an EBIT-margin before special items[*] of 26.4%, and ROIC including goodwill before

  • Globe Newswire

    Novozymes and Chr. Hansen to combine and create a leading global biosolutions partner

    Today, Novozymes and Chr. Hansen have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. The combination is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large. COPENHAGEN, Denmark – December 12, 2022. The proposed combination of Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") will create a strong biosolutions group wi